Table 1 Clinical characteristics and sequencing timelines for pediatric cohort

Participant characteristics	N (#)	Range or proportion (%)
Age (years)
Median age at diagnosis	8.8	0.3–20.7 years
Median age at enrollment	13.8	0.5–21.2 years
Sex
Male	46	58.2
Female	33	41.8
Priority for biopsy per patient (n = 79 patients)
POG	20	25.3
Clinical	56	70.1
Both	2	2.6
Not applicable	1	1.3
Tumor type (n = 83 samples^a)
RMS/STS	13	15.7
Bone sarcoma	12	14.5
Neuroblastoma	9	10.8
High grade CNS	16	19.3
Low grade CNS	4	4.8
Benign	8	9.6
Leukemia	4	4.8
Lymphoma	2	2.4
Other solid	15	18.1
Tumor category (n = 83 samples^a)
Solid	49	59.0
CNS	19	22.9
Heme	6	7.2
Benign	9	10.8
Tumor sample sequencing time point (n = 83 samples^a)
At initial diagnosis	27	32.5
At progression/relapse	56	67.5
Turnaround time to MTB meeting (days) (n = 83 samples)
30–60	20	24.1
61–90	43	51.8
91–120	12	14.5
120+^b	2	2.4
No MTB^c	6	7.2
Median MTB turnaround time (days)	71
Turnaround time to TGR results (days) (n = 83 samples)
0–30	27	32.5
31–60	43	51.8
61–90	3	3.6
91–120	1	1.2
No TGR	9	10.8
Median TGR turnaround time (days)	34

RMS/STS rhabdomyosarcoma/soft-tissue sarcoma, CNS central nervous system, TGR Targeted Gene Report, MTB Molecular Tumor Board.
^aOne patient had two tumors biopsied from different regions of the body; three patients had two samples sequenced at different times.
^bOne case was de-prioritized following the patient’s death.
^cFour patients died in <3 weeks from the time of sample receipt and a formal MTB was not scheduled.

Quick links

Search